direct antithrombins

     

Select
Display
Trial Studied trt Control trt patientstagsNCTROB Result

atrial fibrillation

dabigatran
RE-LY (110mg), 2009dabigatran 110mgwarfarin standard doseNCT00262600Risk of bias suggesting
PETRO (150mg), 2007dabigatran 150mgwarfarin standard doseExploratory -
RE-LY (150mg), 2009dabigatran 150mgwarfarin standard doseNCT00262600Risk of bias suggesting
ximelagatran
SPORTIF II (ximelagatran vs warfarin standard dose), 2002ximelagatranwarfarin standard doseRisk of bias -
SPORTIF III, 2003ximelagatranwarfarin standard doseRisk of bias suggesting
SPORTIF V, 2005ximelagatranwarfarin standard doseLow risk of bias suggesting

DVT prophylaxis

dabigatran
RE-NOVATE (150mg), 2007dabigatran 150mgenoxaparinNCT00168818Low risk of bias negative
RE-NOVATE (220mg), 2007dabigatran 220mgenoxaparinNCT00168818Low risk of bias negative
RE-NOVATE 2dabigatran 220mgenoxaparinNCT00657150Low risk of bias negative
RE-MODEL (150mg), 2007dabigatran 150mgenoxaparin (europe regimen)Low risk of bias negative
RE-MODEL (220mg), 2007dabigatran 220mgenoxaparin (europe regimen)Low risk of bias negative
RE-MOBILIZE (150mg), 2008dabigatran 150mgenoxaparin (US regimen)Low risk of bias negative
RE-MOBILIZE (220mg), 2008dabigatran 220mgenoxaparin (US regimen)Low risk of bias negative
ximelagatran
METHRO I, 2002ximelagatranDalteparinnegative
METHRO II, 2002ximelagatranDalteparinsuggesting
Phase II (Heit), 2001ximelagatranEnoxaparinnegative
Platinum (Colwell), 2003ximelagatranEnoxaparinnegative
METHRO III, 2002ximelagatranEnoxaparinnegative
EXPRESS, 2003ximelagatranEnoxaparinsuggesting